KLRC1 and neoplasm: As intravenously administrated NKG2A-targeted IL-2Rβγ agonist might be captured by NKG2A- and/or IL-2βγ-expressing cells in blood, which would reduce the tumor uptake of NKG2A-targeted IL-2Rβγ agonist, the expression profiles of NKG2A and IL-2βγ in PBMCs of mice bearing MC38 (Figure 2) or B16/F1 (Figure S3) tumor grafts were also examined and compared to those of NKG2A and IL-2βγ in tumor-infiltrated immune cells.